Insilico Medicine vs Recursion Pharmaceuticals
A side-by-side look at scores, pricing and features — with RECATOOLS' ASEAN-aware verdict for each.
|
|
Recursion Pharmaceuticals
Publicly traded techbio company (NASDAQ: RXRX) industrialising drug di...
Visit
|
|
|---|---|---|
| RECATOOLS Score | 8.7 / 10 | 7 / 10 |
| Capability | — | |
| Value for money | — | |
| Ease of use | — | |
| ASEAN readiness | — | |
| API quality | — | |
| Pricing | Enterprise | Enterprise |
| Free tier | Chemistry42 cloud offers academic/startup access tiers; contact required | — |
| Paid from | Enterprise licensing; upfront deals from $10M milestone to $115M (Lilly) | Partnership / collaboration deals (not a self-serve product) |
| Has API | ✓ | ✗ |
| Open source | ✗ | ✗ |
| Free to use | ✗ | ✗ |
| Users | 13 of top 20 global pharma cos; 18.3% YoY subscription growth (2025) | — |
| Founded | 2014 | 2013 |
| Maker | Insilico Medicine (independent; HKEX: 3696) | Chris Gibson |
| Verdict | Insilico Medicine holds a lead no other AI-native drug company currently matches: a molecule it designed from scratch has reached Phase III, with published peer-reviewed efficacy data behind it. The Pharma.AI stack — Pan... |
What this is for: AI-driven, industrial-scale drug discovery combining large biological datasets, automated experiments and its own supercomputing. Who this is for: Pharmaceutical and biotech partners, plus investors in... |
| Full review → | Full review → |
← Back to AI Directory
Comparisons cover up to 4 tools. Scores are RECATOOLS editorial assessments; verify current pricing on each vendor's site.